IMGN-779 is the significant therapeutic option in acute blood cancer arena. This unique naked antibody selectively targets CD33, the antigen expressed by nearly all AML cells. Distinct from typical antibody-drug https://www.targetmol.com/compound/anti_cd33_antibody__imgn_779_naked_antibody_